Tech Company Financing Transactions
Basilea Pharmaceutica Funding Round
Carb-X joined a $6 million capital raise for Basilea Pharmaceutica. The round was announced on 4/9/2026.
Transaction Overview
Company Name
Announced On
4/9/2026
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Undisclosed
Investors
Carb-X (Richard Alm)
Proceeds Purpose
The additional non-dilutive funding will support the first-in-human phase 1 clinical study of Basilea's novel antibiotic BAL2420 (LptA inhibitor)1 and related activities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Hegenheimermattweg 167b
Allschwil, 4123
Switzerland
Allschwil, 4123
Switzerland
Phone
Website
Email Address
Overview
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea has about 190 employees. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 4/9/2026: TeiaCare venture capital transaction
Next: 4/9/2026: CertifID venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








